BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20518604)

  • 1. Narcolepsy in Parkinson's disease.
    Haq IZ; Naidu Y; Reddy P; Chaudhuri KR
    Expert Rev Neurother; 2010 Jun; 10(6):879-84. PubMed ID: 20518604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
    Nishino S; Kanbayashi T
    Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency.
    Knudsen S; Gammeltoft S; Jennum PJ
    Brain; 2010 Feb; 133(Pt 2):568-79. PubMed ID: 20129934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness?
    Wienecke M; Werth E; Poryazova R; Baumann-Vogel H; Bassetti CL; Weller M; Waldvogel D; Storch A; Baumann CR
    J Sleep Res; 2012 Dec; 21(6):710-7. PubMed ID: 22747735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Narcolepsy and the hypocretins.
    Wurtman RJ
    Metabolism; 2006 Oct; 55(10 Suppl 2):S36-9. PubMed ID: 16979425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypocretin deficiency in narcolepsy with cataplexy is associated with a normal body core temperature modulation.
    Grimaldi D; Agati P; Pierangeli G; Franceschini C; Guaraldi P; Barletta G; Vandi S; Cevoli S; Plazzi G; Montagna P; Cortelli P
    Chronobiol Int; 2010 Sep; 27(8):1596-608. PubMed ID: 20854137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration.
    Yasui K; Inoue Y; Kanbayashi T; Nomura T; Kusumi M; Nakashima K
    J Neurol Sci; 2006 Dec; 250(1-2):120-3. PubMed ID: 17005202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Narcolepsy with cataplexy].
    Dauvilliers Y; Arnulf I
    Rev Neurol (Paris); 2008; 164(8-9):634-45. PubMed ID: 18805301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypocretin (orexin) loss in Parkinson's disease.
    Fronczek R; Overeem S; Lee SY; Hegeman IM; van Pelt J; van Duinen SG; Lammers GJ; Swaab DF
    Brain; 2007 Jun; 130(Pt 6):1577-85. PubMed ID: 17470494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease.
    Asai H; Hirano M; Furiya Y; Udaka F; Morikawa M; Kanbayashi T; Shimizu T; Ueno S
    Clin Neurol Neurosurg; 2009 May; 111(4):341-4. PubMed ID: 19097685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanin concentrating hormone in central hypersomnia.
    Peyron C; Valentin F; Bayard S; Hanriot L; Bedetti C; Rousset B; Luppi PH; Dauvilliers Y
    Sleep Med; 2011 Sep; 12(8):768-72. PubMed ID: 21697009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Undetectable levels of CSF hypocretin-1 (orexin-A) in two prepubertal boys with narcolepsy.
    Tsukamoto H; Ishikawa T; Fujii Y; Fukumizu M; Sugai K; Kanbayashi T
    Neuropediatrics; 2002 Feb; 33(1):51-2. PubMed ID: 11930279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excessive daytime sleepiness in Parkinson's disease: characteristics and determinants.
    Poryazova R; Benninger D; Waldvogel D; Bassetti CL
    Eur Neurol; 2010; 63(3):129-35. PubMed ID: 20090346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the hypothalamic neuropeptides hypocretin/orexin in the sleep-wake cycle.
    Salin-Pascual RJ
    Isr Med Assoc J; 2001 Feb; 3(2):144-6. PubMed ID: 11344826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between CSF hypocretin levels and hypocretin neuronal loss.
    Gerashchenko D; Murillo-Rodriguez E; Lin L; Xu M; Hallett L; Nishino S; Mignot E; Shiromani PJ
    Exp Neurol; 2003 Dec; 184(2):1010-6. PubMed ID: 14769395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease comorbid with narcolepsy presenting low CSF hypocretin/orexin level.
    Maeda T; Nagata K; Kondo H; Kanbayashi T
    Sleep Med; 2006 Dec; 7(8):662. PubMed ID: 17097921
    [No Abstract]   [Full Text] [Related]  

  • 17. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions.
    Zeitzer JM; Nishino S; Mignot E
    Trends Pharmacol Sci; 2006 Jul; 27(7):368-74. PubMed ID: 16766052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia.
    Compta Y; Santamaria J; Ratti L; Tolosa E; Iranzo A; Muñoz E; Valldeoriola F; Casamitjana R; Ríos J; Marti MJ
    Brain; 2009 Dec; 132(Pt 12):3308-17. PubMed ID: 19858078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypocretin/orexin, sleep and narcolepsy.
    Hungs M; Mignot E
    Bioessays; 2001 May; 23(5):397-408. PubMed ID: 11340621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter.
    Baumann CR; Bassetti CL
    Sleep Med Rev; 2005 Aug; 9(4):253-68. PubMed ID: 15979356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.